Dalmau, J, Gleichman, AJ, Hughes, EG, Rossi, JE, Peng, X, Lai, M, et al.
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol
2008; 7: 1091–8.
Gable, MS, Gavali, S, Radner, A, Tilley, DH, Lee, B, Dyner, L, et al.
Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis
2009; 28: 1421–9.
Fink, M, Taylor, MA.
The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci
2001; 251 (suppl 1): I8–13.
Peralta, V, Campos, MS, de Jalon, EG, Cuesta, MJ.
DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res
2010; 118: 168–75.
Chapman, MR, Vause, HE.
Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry
2011; 168: 245–51.
Zandi, MS, Irani, SR, Lang, B, Waters, P, Jones, PB, McKenna, P, et al.
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol
2011; 258: 686–8.
Föcking, M, Dicker, P, English, JA, Schubert, KO, Dunn, MJ, Cotter, DR.
Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry
2011; 68: 477–88.
Schubert, KO, Föcking, M, Prehn, JH, Cotter, DR.
Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry
2011; Oct 11, doi: 10.1038/mp.2011.123 (Epub ahead of print).